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Although nuclear cardiology is generally considered as a clinical specialty since approximately four decades, the initial application of radioisotopes to the study of blood circulation in humans (pulmonary circulation time) was reported almost a century ago in 1927. Blumgart and Weiss 1 used radon gas dissolved in saline solution as the radiotracer and a modified Wilson cloud chamber as the radiation detector. Two decades later, in 1949, Prinzmetal et al. 2 used sodium iodide probes and radiolabeled albumin to measure cardiac output and blood volumes. These important initial studies provided the roots of nuclear cardiology which extended its applications not only to heart function and blood circulation but now to the non-invasive imaging of myocardial perfusion, infarct, myocardial viability, cardiac inflammation, and cardiac metabolism with the use of various radiotracers.
MYOCARDIAL PERFUSION IMAGING
Myocardial perfusion imaging (MPI) represented and still represents the vast majority of nuclear cardiologic procedures performed every year in clinical laboratories throughout the world. Myocardial perfusion scintigraphy has significantly evolved since its introduction more than four decades ago. 3 Three major factors have more specifically contributed to this evolution: (1) technical improvements in SPECT scintigraphic data acquisition and analysis, (2) introduction of new technetium-99m-labeled MPI radiopharmaceuticals with different properties than thallium-201, and (3) more recently, availability of PET radiotracers and PET dedicated cameras. In the last four decades, several studies have been performed on various types of radiotracers but we can ask the question: why do we still need new radiotracers for MPI? After all, four SPECT radiotracers have already been approved by the Food and drugs administration (FDA) for clinical use:  201 Thallium,  99m Tc-Sestamibi,  99m Tc-Tetrofosmin, and 99m Tc-Teboroxime, and two PET agents (Rubidium-82 and N-13 Ammonia) as well. Table 1 summarizes the most important characteristics of an « ideal » SPECT or PET radiotracer for MPI. Although the currently available radiotracers show many of the characteristics of the « ideal » radiotracer, none of them have all the desired ones. All of the current FDA-approved SPECT radiotracers show, at variable degree, the « roll-off » phenomenon at high flow rates which can limit the detection of ischemia in some patients with multivessel disease or mild-to-moderate CAD, especially at high flow rates, as those seen with pharmacological intervention. 4, 5 PET radiotracers are increasingly used for MPI, given the broader clinical access to PET cameras.
6 N-13-Ammonia is a valuable radiotracer for assessing either relative myocardial uptake or measuring absolute myocardial blood flow (with dynamic acquisition and application of multiple-compartment kinetic models). However, the use of N-13-Ammonia requires an on-site cyclotron (because of its physical half-life of 10 minute), thus limiting its use to a very restricted number of sites. Rubidium-82, another PET MPI radiotracer, does not require on-site cyclotron as it is produced with a Strontium-82/Rubidium-82 generator. Rubidium-82 possesses the unique advantage of having a very short half-life of 75 second, allowing for a complete rest-stress MPI study within 30 minute. Although qualitative assessment of relative Rubidium-82 perfusion defects shows a good correlation with those obtained with radiolabeled microspheres or O-15 water, and that the diagnostic accuracy of Rubidium-82 imaging in clinical detection of CAD is high, net myocardial uptake of this radiotracer plateaus at the hyperemic flows often achieved with pharmacological stress. Furthermore, its very long positron range decreases the spatial resolution and Rubidium-82 has a lower myocardial extraction than N-13-Ammonia. Therefore, it is not surprising to see a quest for the ideal or near optimal MPI PET radiotracer. One very promising agent, 18 FFlurpiridaz, an analog of mitochondrial complex I inhibitors, is currently under clinical investigation (Phases III). This radiotracer possesses many of the characteristics of the « ideal » MPI radiotracer although clinical data on its diagnostic accuracy are still needed before we can conclude on its future in clinical practice as the best available MPI radiotracer. [9] [10] [11] Because of the longer half-life of 18 F, 18 F-Flurpiridaz does not require an on-site cyclotron. Results of the 18 F-Flurpiridaz phase III trials would be of high importance to determine its future clinical roles.
In the mean time, it could be interesting to see if it is possible to give a « second birth » to an older compound which has been approved by the FDA a few weeks after 99m Tc-sestamibi has been approved in the early 1990s, 99m Tc-Teboroxime, a member of the boronic acid adducts of technetium dioxime complexes (BATO) with a neutral charge and high lipophilicity. 99m Tc-Teboroxime is a freely diffusible tracer with a very high extraction fraction over a wide range of coronary blood flow rates, higher than that of 99m Tcsestamibi, 99m Tc-tetrofosmin, and 201 Thallium. However, the myocardial half-life of 99m Tc-teboroxime is approximately 9 minute, 12,13 which gives a very narrow time window for optimal imaging (particularly with a liver clearance of 5-6 minute). This significant drawback limited the clinical use of this agent. However, Table 1 . Criteria for the « ideal » SPECT and PET myocardial perfusion imaging radiotracer (A) Physiological characteristics 1. High myocardial uptake with no or minimal myocardial redistribution, especially during the data acquisition time period 2. Linear relationship between radiotracer myocardial uptake and coronary blood flow (up to 5 mL/min/g, which is the maximal level seen with pharmacological vasodilation). This requires a high first-pass myocardial extraction and subsequent very rapid blood clearance 3. A high target-to-background ratio with low uptake in the adjacent organs (lungs, liver, stomach, and bowels. This high ratio should be maintained throughout the entire imaging protocol, especially if a same day rest-stress or stress-rest protocol is to be performed 4. Quantification of absolute myocardial blood flow, enabling identification of diffuse, multivessel, or balanced CAD. Perhaps more importantly, absolute myocardial blood flow and coronary flow reserve identify patient with suboptimal response to pharmacological stress and provides incremental prognosis information over perfusion alone 5. The effect of blood flow on myocardial transport of the radiotracer must be predominant to the effect of metabolic cellular alterations 
CARDIAC METABOLISM
Different facets of cardiac metabolism have been studied with radiotracers. In the current issue of the Journal, Manabe et al.
14 comprehensively reviewed the various radiotracers that are used to evaluate cardiac metabolism. Since the heart derives its energy from a variety of sources such as free fatty acids, glucose, lactate, and ketone bodies, it is possible to study cardiac metabolism using these sources. SPECT radiotracers include 123 I-BMIPP (beta-methyl-p-iodophenylpentadecanoic acid) and 123 I-IPPA (iodophenylpentadecanoic acid), whereas PET tracers include 18 F-FDG (fluorodeoxyglucose), 11 C-Palmitate, 18 F-FTHA (fluoro-6-thia-heptadecanoic acid), and 11 C-Acetate. Although SPECT imaging of fatty acid myocardial metabolism with 123 I-BMIPP and 123 I-IPPA has gained in popularity in Japan, there are not still approved by the FDA, limiting their clinical applications.
123 I-IPPA demonstrates a rapid accumulation in the heart and a clearance pattern that follows a biexponential function characteristic of 11 C-Palmitate. The clearances rate correlates directly with B-oxidation. Unfortunately, the poor temporal resolution of SPECT systems did not take advantage of the rapid turnover of 123 I-IPPA and quantification of myocardial fatty metabolism was not possible and image quality was reduced.
123 I-BMIPP, a branch-chain analog of 123 I-IPPA, 15 shows increased radiotracer retention and improved image quality but is it not optimal. 16 Here, again, the new SPECT technology with fast data acquisition and new image-qualityimproving methods and software could be advantageous with these « older » radiotracers. With technical improvements, fatty acid metabolic imaging could be more useful, especially in cardiac risk stratification and follow-up of treatment of patients with diabetes mellitus, obesity, insulin resistance, hypertension, left ventricular hypertrophy, non-ischemic dilated cardiomyopathy, and ischemia (detection of « ischemic memory »). 17 In order to become an indispensible clinical tool in the diagnosis, risk stratification, and monitoring of therapy in many specific types of populations, radionuclide evaluation of the cardiac metabolism will need to move beyond viability assessment. This can be achieved only with large specific clinical trials where new technologies would be applied.
Non-invasive radionuclide metabolic imaging is a perfect example of the continued necessity for a parallel development in dedicated radiotracers, improved imaging devices, and application of more complex compartmental modeling which, ultimately, will permit more complete characterization of the metabolism of a given substrate to analyze. Dynamic data acquisitions with further increased counting statistics will be essential if optimal quantitative parameters are to be used in a clinical environment and have a real clinical impact in the day-to-day practice. Ideally, new radiotracers will be designed in order to provide new clinically oriented insights into the linkage between various substrate metabolism and cell growth, cell survival, and energy transfer.
CARDIAC INNERVATION
The heart is richly innervated by sympathetic and parasympathetic fibers. Neurohormonal processes control cardiac output, vascular tone, and blood volume. Radionuclide imaging offers a unique way to provide important insight into the pathophysiology of various cardiac diseases by visualizing the sympathetic innervation of the heart.
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123 I-MIBG (metaiodobenzylguanidine), approved by the FDA in 2013, is available and the preferred agent used in clinical practice. The current key semi-quantitative parameters for 123 I-MIBG cardiac imaging are the heart-to-mediastinum ratio and myocardial washout. 19, 20 These parameters are subject to specific imaging parameters and must be standardized according to the type of imaging device used in order to be clinically useful and accurate. Although probably underutilized in clinical practice, 123 I-MIBG cardiac imaging shows very great clinical uses and potential. Travin 21 elegantly summarized the demonstrated and the potential clinical uses of cardiac adrenergic imaging.
123 I-MIBG cardiac imaging proved to be very useful not only in assessing patients with heart failure and low ejection fraction (and risk stratification in terms of cardiac events) or risk stratification in patients with ventricular arrhythmias associated with heart failure but also in evaluating patients post-cardiac transplant, patients with primary arrhythmic diseases, myocardial ischemia, diabetes mellitus, and the monitoring of chemotherapy toxic effects.
123 I-MIBG show some minor imaging drawbacks, especially related to the various energy peaks of iodine (with septal penetration of the 529 keV higher energy photons) and high liver uptake, both representing some limitations to optimal SPECT imaging. Therefore, different PET radiotracers have been developed for evaluating presynaptic neuronal function such as 11 C-HED (hydroxyephedrine), 18 F-LMI 1195 (bromo-fluoropropoxy benzyl guanidine), 18 F-Fluorometaraminol, 11 C-phenylephrine, 18 F-fluorodopamine, and 11 C-epinephrine. These agents are mostly used in research projects. Other radiotracers have been developed for assessing postsynaptic neuronal functions and parasympathetic nervous system but their clinical usefulness has not been established yet. Therefore, although not the « ideal » agent, 123 I-MIBG still remains a very good clinical tool for imaging of cardiac innervation.
INFLAMMATION, INFILTRATIVE DISEASE, ATHEROSCLEROSIS, AND OTHER DISEASES
Over the last decade, nuclear cardiac imaging has expended significantly with the development of unique and targeted molecular imaging techniques, especially in the evaluation of infiltrative and inflammatory cardiac diseases. It is likely that the use of nuclear cardiologic procedures will significantly expand in the very near future in various fields such as detection of apoptosis, vascular remodeling, angiogenesis, and evaluation of the vascular plaque.
Nuclear cardiology is already actively involved in the evaluation of cardiac amyloidosis with 99m TcPyrophosphate, 123 I-MIBG, 18 F-NaF, and amyloid binding radiotracers ( 99m Tc-aprotinin, 123 I-serum amyloid P component or SAP, 11 C Pittsburgh B compound, 18 Fflorbetapir, 18 F-flumetamol, and 18 F-florbetaben). The latter three radiotracers have been recently approved by the FDA for beta-amyloid imaging of the brain in patients with Alzheimer's disease but not for cardiac amyloidosis. Their clinical availability will certainly help to prompt evaluation of cardiac infiltration as well.
Myocarditis Anatomic imaging techniques of atherosclerosis have a very limited capacity to identify the hallmarks of the vulnerable plaque. Nuclear cardiology has a unique opportunity to play a pivotal role in the non-invasive assessment of the vulnerable plaque given its ability for molecular imaging. The accumulation of lipids and inflammatory cells within discrete areas of the intima offers potential targets to specifically designed radiotracers. The association of local presence of high macrophage density, lipid-rich necrotic core, neovascularization, micro-calcifications, remodeling, and a thin fibrous cap are the perfect ingredients for the rupture of a high-risk vulnerable atherosclerotic plaque. 24 Most of the studies for atherosclerosis evaluation are performed with 18 F-FDG PET/CT for large vessel imaging. Detection of 18 F-FDG into coronaries is much more technically challenging and limited by interference from normal radiotracer uptake, the quality of the diet preparation, cardiac and respiratory motions (problem for co-registration between PET and CT), and the limited spatial resolution. Therefore, there is a huge clinical need for a more specific and dedicated radiotracer for vulnerable cardiac plaque detection.
Manabe et al. 14 also discussed the potential use of many other radiotracers, which is beyond the scope of this article. Most of them unfortunately are only in the early stages of animal or human pre-clinical studies, and based on the historical development of radiotracers during the last several decades, only a very few of them will go through all the necessary steps for approval in human studies and ultimately being used in a day-to-day clinical practice. The ideal radiotracer used to study a specific aspect or evaluate cardiologic disease might not necessarily be found in a very near future, given all the numerous characteristics involved and the complexity of the pathophysiology to evaluate as well. However, current and significant advances in imaging devices (including hybrid PET, CT, MR imaging, specially dedicated collimators, and new CZT cameras) and newly improved methods of imaging acquisition and analysis can certainly help to improve the relatively minor « imperfections » of the currently available or potential new radiotracers. Dedicated imaging devices to cardiac imaging, (not only for humans but also for small animal studies such as micro-SPECT and micro-PET cameras coupled to hybrid imaging with CT or MRI) will be essential in both research and clinical studies.
CONCLUSION
In order to advance and thrive, nuclear cardiology needs to go beyond myocardial perfusion imaging which is well established and recognized in the diagnosis and risk stratification of patients with CAD. The ability to image the underlying molecular processes of cardiac diseases is a unique and formidable strength of nuclear cardiology. The quest for the « ideal » radiotracer for myocardial perfusion imaging, cardiac metabolism evaluation, cardiac innervation, inflammation, atherosclerosis, etc., must continue. A close collaboration between radiopharmaceuticals and imaging devices developers and researchers is needed in order to fully take advantage of the unique ability of nuclear cardiology to non-invasively assess all the various aspects of cardiac diseases and to increase its clinical relevance.
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